Home/Pipeline/Icosabutate

Icosabutate

Metabolic dysfunction-associated steatohepatitis (MASH)

Phase 3Active

Key Facts

Indication

Metabolic dysfunction-associated steatohepatitis (MASH)

Phase

Phase 3

Status

Active

Company

NorthSea Therapeutics

About NorthSea Therapeutics

NorthSea Therapeutics is a private, late-stage biotech advancing a platform of Structurally Engineered Fatty Acids (SEFAs) designed to overcome the limitations of natural fatty acids as drugs. Its lead assets include Icosabutate (Phase 3 for MASH), Orziloben (Phase 2 for IFALD), and SEFA-1024 (Phase 2 for severe hypertriglyceridemia). The company is positioned in large, underserved markets with a differentiated oral therapeutic approach targeting key liver and metabolic pathways.

View full company profile

Therapeutic Areas

Metabolic Diseases Cholestatic Diseases Fibrotic Diseases Gastroenterology Hepatology

Other Metabolic dysfunction-associated steatohepatitis (MASH) Drugs

Drug	Company	Phase	Status
NGM831 (MK-3655)	NGM Biopharmaceuticals	Phase 2b	Active (Merck-led)
Pegozafermin (BIO89-100)	89bio	Phase 3	Active
Oxy210	MAX BioPharma	Preclinical	Active
NA-941	Biomed	Phase 2A	Active
PRO-MSH-001	ProdIgY Biotech	Discovery	Active
Undisclosed MASH Program	Syndya Therapeutics	Discovery	Active
Partnered Program	Cellarity	Pre-clinical	Active
Lanifibranor	Hepalys	Phase 1	Active (Japan development program)
IW-601	ImmuneWalk Therapeutics	Preclinical	Active
ION224 (IONIS-DGAT2Rx)	Ionis Pharmaceuticals	Phase 2b	Active
ALG-055009	Aligos Therapeutics	Phase 2	Active
CM-101	Chemomab Therapeutics	Phase 2a	Completed